Latest News & Features
Americas
AbbVie has sued Amgen saying its proposed biosimilar for the Humira (adalimumab) drug infringes 61 patents. 8 August 2016
Asia-Pacific
A new fund dedicated to accelerate the development and commercialisation of Australian biomedical discoveries has officially launched. 5 August 2016
Americas
Fustibal, a targeted therapeutics biotechnology start-up, has filed an inter partes review petition challenging a patent owned by German pharmaceutical company Bayer. 4 August 2016
Americas
Editas Medicine, a US genome-editing company, announced yesterday that it has entered into an exclusive licensing agreement with Massachusetts General Hospital to access CRISPR technology. 4 August 2016
Americas
Natco Pharma, an India-based drugs company, announced today that it has received final approval from the US Food and Drug Administration to produce a generic version of Tamiflu. 4 August 2016
Americas
Inter-partes reviews (IPRs) can be a powerful weapon against patents listed in the Orange Book. However, IPR practice favours a petitioner who has carefully thought about the issues and crafted the best strategy, says Mark Remus of Brinks Gilson & Lione. 4 August 2016
Americas
Pfizer has acquired Bamboo Therapeutics, a biotechnology company based in North Carolina. 3 August 2016
Americas
Teva’s acquisition of Allergan’s generic business has been completed, the company revealed yesterday. 3 August 2016
Big Pharma
The English High Court has today said that National Health Service England should finance an important therapy used to treat patients suffering from HIV. 2 August 2016
Europe
The English High Court has referred two questions on supplementary protection certificates to the Court of Justice of the European Union in a case between Merck Sharp & Dohme and the UK Intellectual Property Office. 2 August 2016